SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 28, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically concerning the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan, which is notionally held in GSK Ordinary Share ADRs.
Management Commentary and Risks
Management commentary is limited to the notification of an increase in the notional allocation of Ordinary Share ADRs on August 24, 2007, at a price of $52.22 per ADR share. The transactions involved Mrs. C Bruck Slaoui and Dr. R G Greig, each receiving an allocation of 3 shares. No specific risks, contingencies, or unusual items regarding the company's broader business are disclosed in this text.
Key Facts for Investor Verification
- The filing confirms a transaction date of August 24, 2007, with notification on August 28, 2007.
- The transaction price for the notional ADR allocation was $52.22 per share.
- The affected individuals are Mrs. C Bruck Slaoui and Dr. R G Greig.
- The transaction relates to the US Retirement Savings Plan and complies with Disclosure and Transparency Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).